Home › Research › Tau biomarkers
Neurological and inflammatory biomarkers in CSF along the Alzheimer's Disease spectrum
Catherine Demos, Jermaine Brown, Brian Ngo, Itziar de Rojas, Federico Casales, Victòria Fernández, Josep Blazquez, Miyo K. Chatanaka et al.. Alzheimer s & Dementia, 2025-12-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
For 43 assays, more than 80% of samples provided concentrations within the dynamic range of the assay. We found concentration differences of 30 CSF biomarkers to be statistically significant across cognitive groups, with the most significant groupwise comparisons between the dementia groups (AD and MCI progressors) and the non-dementia groups (MCI non-progressors and SCD). There were 17 analytes for which mean comparisons were statistically different between MCI progressor and non-progressor groups. Ten proteins, pTau217, total tau, neurofilament light, GFAP, MIF, MMP-10, YKL-40, neurofilament heavy, MIP-1α, and IL-15, demonstrated an AUC > 0.7 for differentiation of MCI progressors and non-progressors, showing promise for differentiating MCI individuals at risk of progressing to dementia, with ptau217 being the most significant (AUC > 0.99). Here we present an exploratory study with quantitative immunoassays, where we identified several CSF biomarkers indicative of dementia or progression to dementia covering multiple pathological mechanisms. Further successful integration into a biomarker panel could help personalize treatment, stratify individuals for therapeutic studies and provide a better understanding of how these early pathologies impact disease progression.
What this study adds
Evidence grade: Low
The record lists 100 participants. The authors say these markers could help personalize treatment and stratify people for therapeutic studies, but this is an exploratory biomarker study, not a treatment or cure.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Demos, C., Brown, J., Ngo, B., de Rojas, I., Casales, F., Fernández, V., et al. (2025). Neurological and inflammatory biomarkers in CSF along the Alzheimer's Disease spectrum. Alzheimer s & Dementia. https://doi.org/10.1002/alz70856_097201
Vancouver
Demos C, Brown J, Ngo B, de Rojas I, Casales F, Fernández V, et al. Neurological and inflammatory biomarkers in CSF along the Alzheimer's Disease spectrum. Alzheimer s & Dementia. 2025. doi:10.1002/alz70856_097201. PMID: 41442429.
BibTeX
@article{demos2025-41442429,
author = {Demos, Catherine and Brown, Jermaine and Ngo, Brian and de Rojas, Itziar and Casales, Federico and Fernández, Victòria and Blazquez, Josep and Chatanaka, Miyo K. and others},
title = {{Neurological and inflammatory biomarkers in CSF along the Alzheimer's Disease spectrum}},
journal = {Alzheimer s \& Dementia},
year = {2025},
doi = {10.1002/alz70856_097201},
pmid = {41442429},
url = {https://doi.org/10.1002/alz70856_097201}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- For 43 assays, more than 80% of samples provided concentrations within the dynamic range of the assay.
- We found concentration differences of 30 CSF biomarkers to be statistically significant across cognitive groups, with the most significant groupwise comparisons between the dementia groups (AD and MCI progressors) and the non-dementia groups (MCI non-progressors and SCD).
- There were 17 analytes for which mean comparisons were statistically different between MCI progressor and non-progressor groups.
- Ten proteins, pTau217, total tau, neurofilament light, GFAP, MIF, MMP-10, YKL-40, neurofilament heavy, MIP-1α, and IL-15, demonstrated an AUC > 0.7 for differentiation of MCI progressors and non-progressors, showing promise for differentiating MCI individuals at risk of progressing to dementia, with ptau217 being the most significant (AUC > 0.99).
- Here we present an exploratory study with quantitative immunoassays, where we identified several CSF biomarkers indicative of dementia or progression to dementia covering multiple pathological mechanisms.
Why it matters
In this exploratory study of cerebrospinal fluid, 30 biomarkers differed significantly across cognitive groups, and 10 proteins including pTau217, total tau, neurofilament light and GFAP distinguished people with mild cognitive impairment who progressed to dementia from those who did not, with ptau217 performing best. The authors say these markers could help personalize treatment and stratify people for therapeutic studies, but this is an exploratory biomarker study, not a treatment or cure.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants100
- Evidence strengthLow
How this study scored 38/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 100 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Jacob N. Wohlstadter: h-index 10 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of Toronto: institution h-index 1,923 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 6 institution(s) in 3 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41442429) |
| Free to read | 2 / 2 | Free to read |
| Total | 38 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1002/alz70856_097201
- PubMed: 41442429
- Original source →
- Free full text: Alzheimer s & Dementia →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Tau biomarkers from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.